Adding Daratumumab to Bortezomib and Dexamethasone Markedly Improves Outcomes in Recurrent/Refractory Multiple Myeloma
Initial findings from a pivotal phase III trial showed that daratumumab (Darzalex) added to a standard two-drug regimen (bortezomib [Velcade] and dexamethasone) markedly improved outcomes for patients with recurrent or refractory multiple myeloma.Â
The ASCO Post
In The News
American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting